Literature DB >> 17325476

Gliosarcoma arising in oligodendroglial tumors ("oligosarcoma"): a clinicopathologic study.

Fausto J Rodriguez1, Bernd W Scheithauer, Robert Jenkins, Peter C Burger, Peter Rudzinskiy, Euvgeni Vlodavsky, Adam Schooley, Joseph Landolfi.   

Abstract

Gliosarcomas are morphologically biphasic tumors composed of glial and sarcomatous elements. Only rare examples of gliosarcoma with oligodendroglial components have been reported. Seven patients with oligodendroglial tumors and a sarcomatous component were identified. Fluorescence in situ hybridization for 1p/19q was sought in glial and sarcomatous regions in all cases. Their mean age at diagnosis of gliosarcoma was 48 years (range 36 to 68) (F:M ratio=5:2). At first resection, the tumors included grade II oligodendroglioma (n=3), grade III oligodendroglioma (n=1), grade II oligoastrocytoma (n=1), and grade III oligoastrocytoma (n=2). The sarcomatous component developed in recurrent/progressive tumors in 6 cases but was a focal finding at first tumor resection in 1 and included fibrosarcoma (n=5), leiomyosarcoma (n=1), or pleomorphic myogenic sarcoma (n=1). Rhabdoid change was a focal finding in the sarcomatous component of 1 tumor. The glial component expressed both glial fibrillary acidic protein and S-100 in all cases, whereas the sarcomatous component at least focally showed smooth muscle actin (n=6), CD34 (n=4), S-100 protein (n=3), and epithelial membrane antigen (n=2) reactivity. Fluorescence in situ hybridization studies demonstrated 1p/19q codeletion in 5 cases, showed no evidence of deletion in 1 case, and technically failed in 1 case. Three of the 5 cases demonstrated 1p/19q codeletion in the sarcomatous component as well. Gliosarcomas with oligodendroglial elements are rare. The relatively frequent presence of 1p/19q codeletion in both glial and sarcomatous components supports the notion that the sarcomatous component represents a metaplastic change occurring in the glial element, the same mechanism active in classic astrocytic gliosarcomas.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17325476     DOI: 10.1097/01.pas.0000213378.94547.ae

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  12 in total

1.  Primary gliosarcoma of the brain: radiologic and histopathologic features.

Authors:  Alfredo E Romero-Rojas; Julio A Diaz-Perez; Lina M Ariza-Serrano; Deirdre Amaro; Alfonso Lozano-Castillo
Journal:  Neuroradiol J       Date:  2013-12-18

2.  Clinical outcome of gliosarcoma compared with glioblastoma multiforme: a clinical study in Chinese patients.

Authors:  Guobin Zhang; Shengyue Huang; Junting Zhang; Zhen Wu; Song Lin; Yonggang Wang
Journal:  J Neurooncol       Date:  2016-01-02       Impact factor: 4.130

Review 3.  Gliosarcoma of the cerebellar hemisphere: a case report and review of the literature.

Authors:  Sung Kyoung Moon; Eui Jong Kim; Woo Suk Choi; Chang Woo Ryu; Bong Jin Park; Juhie Lee
Journal:  Korean J Radiol       Date:  2010-08-27       Impact factor: 3.500

4.  Gliosarcoma With Glioneuronal and Rhabdomyosarcoma Components.

Authors:  Murad Alturkustani
Journal:  Cureus       Date:  2022-07-09

5.  High-grade glioma before and after treatment with radiation and Avastin: initial observations.

Authors:  Ingeborg Fischer; Clare H Cunliffe; Robert J Bollo; Shahzad Raza; David Monoky; Luis Chiriboga; Erik C Parker; John G Golfinos; Patrick J Kelly; Edmond A Knopp; Michael L Gruber; David Zagzag; Ashwatha Narayana
Journal:  Neuro Oncol       Date:  2008-08-12       Impact factor: 12.300

6.  Identification of t(1;19)(q12;p13) and ploidy changes in an ependymosarcoma: a cytogenetic evaluation.

Authors:  Abeer Z Tabbarah; Austin W Carlson; Angelica Oviedo; Rhett P Ketterling; Fausto J Rodriguez
Journal:  Clin Neuropathol       Date:  2012 May-Jun       Impact factor: 1.368

7.  Cerebral high-grade oligodendroglioma with sarcomatous transdifferentiation ("oligosarcoma") in a boxer dog.

Authors:  A Fadda; I Vajtai; J Lang; D Henke; A Oevermann
Journal:  J Vet Intern Med       Date:  2014 Nov-Dec       Impact factor: 3.333

8.  Adjuvant Radiation Therapy and Temozolomide in Gliosarcoma: Is It Enough? Case Series of Seven Patients.

Authors:  Himanshu Srivastava; Abhinav Dewan; Surender Kumar Sharma; Preety Negi; Ajay Kumar Dewan; Sunil Pasricha; Krati Mehrotra
Journal:  Asian J Neurosurg       Date:  2018 Apr-Jun

9.  Cerebral gliosarcoma with perivascular involvement in a cat.

Authors:  Patricia Álvarez; Annette Wessmann; Mireia Pascual; Oriol Comas; Dolors Pi; Martí Pumarola
Journal:  JFMS Open Rep       Date:  2019-10-10

Review 10.  Primary gliosarcoma: key clinical and pathologic distinctions from glioblastoma with implications as a unique oncologic entity.

Authors:  Seunggu J Han; Isaac Yang; Tarik Tihan; Michael D Prados; Andrew T Parsa
Journal:  J Neurooncol       Date:  2009-07-18       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.